Studies have shown that liver-specific expression of transcriptionally active Srebf1c promotes development of fatty liver and increased visceral mass [45], and mice expressing nuclear Srebf1c developed fatty liver [46] and liver-specific Srebf2 knockout mice exhibit reduced cholesterol and fatty acid synthesis [47]. Here, SREBF2 is linked to fatty liver disease.